138 related articles for article (PubMed ID: 37247580)
21. Incidence, Clinicopathologic Features, HER2 Fluorescence In Situ Hybridization Profile, and Oncotype DX Results of Human Epidermal Growth Factor Receptor 2-Low Breast Cancers: Experience From a Single Academic Center.
Hu Y; Jones D; Zhao W; Tozbikian G; Wesolowski R; Parwani AV; Li Z
Mod Pathol; 2023 Jul; 36(7):100164. PubMed ID: 36967073
[TBL] [Abstract][Full Text] [Related]
22. Comparison of breast cancer HER-2 receptor testing with immunohistochemistry and in situ hybridization.
Shanmugalingam A; Hitos K; Pathmanathan N; Edirimmane S; Hughes TM; Ngui NK
Breast Cancer Res Treat; 2023 Feb; 198(1):143-148. PubMed ID: 36604351
[TBL] [Abstract][Full Text] [Related]
23. ER, HER2, and TOP2A expression in primary tumor, synchronous axillary nodes, and asynchronous metastases in breast cancer.
Jensen JD; Knoop A; Ewertz M; Laenkholm AV
Breast Cancer Res Treat; 2012 Apr; 132(2):511-21. PubMed ID: 21667123
[TBL] [Abstract][Full Text] [Related]
24. HER2-low inflammatory breast cancer: Clinicopathologic features and prognostic implications.
Tarantino P; Niman SM; Erick TK; Priedigkeit N; Harrison BT; Giordano A; Nakhlis F; Bellon JR; Parker T; Strauss S; Jin Q; King TA; Overmoyer BA; Curigliano G; Regan MM; Tolaney SM; Lynce F
Eur J Cancer; 2022 Oct; 174():277-286. PubMed ID: 36116830
[TBL] [Abstract][Full Text] [Related]
25. Breast Cancer With a HER2 FISH Group 2 Result: Should HER2 Tests be Repeated?
Wang M; Ding Q; Gu J; Sfamenos SM; Huo L; Tang Z; Sun H; Robinson M; Tang G; Lim B; Wu Y; Albarracin CT; Sahin AA; Chen H
Clin Breast Cancer; 2023 Jun; 23(4):415-422. PubMed ID: 36878823
[TBL] [Abstract][Full Text] [Related]
26. Differential prognostic value of positive HER2 status determined by immunohistochemistry or fluorescence in situ hybridization in breast cancer.
Stocker A; Trojan A; Elfgen C; Hilbers ML; Moskovszky L; Varga Z
Breast Cancer Res Treat; 2020 Sep; 183(2):311-319. PubMed ID: 32638236
[TBL] [Abstract][Full Text] [Related]
27. A gene-protein assay for human epidermal growth factor receptor 2 (HER2): brightfield tricolor visualization of HER2 protein, the HER2 gene, and chromosome 17 centromere (CEN17) in formalin-fixed, paraffin-embedded breast cancer tissue sections.
Nitta H; Kelly BD; Padilla M; Wick N; Brunhoeber P; Bai I; Singh S; Ranger-Moore J; Bieniarz C; Tsuda H; Grogan TM
Diagn Pathol; 2012 May; 7():60. PubMed ID: 22647525
[TBL] [Abstract][Full Text] [Related]
28. Evolution of low HER2 expression between early and advanced-stage breast cancer.
Tarantino P; Gandini S; Nicolò E; Trillo P; Giugliano F; Zagami P; Vivanet G; Bellerba F; Trapani D; Marra A; Esposito A; Criscitiello C; Viale G; Curigliano G
Eur J Cancer; 2022 Mar; 163():35-43. PubMed ID: 35032815
[TBL] [Abstract][Full Text] [Related]
29. ER staining levels affect HER2 staining and heterogeneity.
Akashi M; Yamaguchi R; Kusano H; Yamaguchi M; Akiba J; Kakuma T; Tanaka M; Akagi Y; Yano H
Breast Cancer; 2021 May; 28(3):720-726. PubMed ID: 33423217
[TBL] [Abstract][Full Text] [Related]
30. Retrospective analysis of metastatic behaviour of breast cancer subtypes.
Savci-Heijink CD; Halfwerk H; Hooijer GK; Horlings HM; Wesseling J; van de Vijver MJ
Breast Cancer Res Treat; 2015 Apr; 150(3):547-57. PubMed ID: 25820592
[TBL] [Abstract][Full Text] [Related]
31. Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial.
Gebhart G; Lamberts LE; Wimana Z; Garcia C; Emonts P; Ameye L; Stroobants S; Huizing M; Aftimos P; Tol J; Oyen WJ; Vugts DJ; Hoekstra OS; Schröder CP; Menke-van der Houven van Oordt CW; Guiot T; Brouwers AH; Awada A; de Vries EG; Flamen P
Ann Oncol; 2016 Apr; 27(4):619-24. PubMed ID: 26598545
[TBL] [Abstract][Full Text] [Related]
32. The assessment of HER2 status in breast cancer: the past, the present, and the future.
Nitta H; Kelly BD; Allred C; Jewell S; Banks P; Dennis E; Grogan TM
Pathol Int; 2016 Jun; 66(6):313-24. PubMed ID: 27061008
[TBL] [Abstract][Full Text] [Related]
33. Predictors of pathological complete response to neoadjuvant treatment and changes to post-neoadjuvant HER2 status in HER2-positive invasive breast cancer.
Katayama A; Miligy IM; Shiino S; Toss MS; Eldib K; Kurozumi S; Quinn CM; Badr N; Murray C; Provenzano E; Callagy G; Martyn C; Millican-Slater R; Purdie C; Purnell D; Pinder SE; Oyama T; Shaaban AM; Ellis I; Lee AHS; Rakha EA
Mod Pathol; 2021 Jul; 34(7):1271-1281. PubMed ID: 33526875
[TBL] [Abstract][Full Text] [Related]
34. Estrogen receptor (ER), progesterone receptor (PR), and HER2 expression pre- and post- neoadjuvant chemotherapy in primary breast carcinoma: a single institutional experience.
Kinsella MD; Nassar A; Siddiqui MT; Cohen C
Int J Clin Exp Pathol; 2012; 5(6):530-6. PubMed ID: 22949935
[TBL] [Abstract][Full Text] [Related]
35. Interobserver Variation in the Assessment of Immunohistochemistry Expression Levels in HER2-Negative Breast Cancer: Can We Improve the Identification of Low Levels of HER2 Expression by Adjusting the Criteria? An International Interobserver Study.
Baez-Navarro X; van Bockstal MR; Nawawi D; Broeckx G; Colpaert C; Doebar SC; Hogenes MCH; Koop E; Lambein K; Peeters DJE; Sinke RHJA; Bastiaan van Brakel J; van der Starre-Gaal J; van der Vegt B; van de Vijver K; Vreuls CPH; Vreuls W; Westenend PJ; van Deurzen CHM
Mod Pathol; 2023 Jan; 36(1):100009. PubMed ID: 36788064
[TBL] [Abstract][Full Text] [Related]
36. Predictive markers in breast cancer: An update on ER and HER2 testing and reporting.
Calhoun BC; Collins LC
Semin Diagn Pathol; 2015 Sep; 32(5):362-9. PubMed ID: 25770732
[TBL] [Abstract][Full Text] [Related]
37. Concordance of breast cancer biomarker status between routine immunohistochemistry/in situ hybridization and Oncotype DX qRT-PCR with investigation of discordance, a study of 591 cases.
Sechrist H; Glasgow A; Bomeisl P; Gilmore H; Harbhajanka A
Hum Pathol; 2020 Oct; 104():54-65. PubMed ID: 32758491
[TBL] [Abstract][Full Text] [Related]
38. Metastatic breast carcinoma in pleural fluid: Correlation of receptor and HER2 status with the primary carcinoma-a pilot study.
Francis IM; Alath P; George SS; Jaragh M; Al Jassar A; Kapila K
Diagn Cytopathol; 2016 Dec; 44(12):980-986. PubMed ID: 27666130
[TBL] [Abstract][Full Text] [Related]
39. Absent progesterone receptor expression in the lymph node metastases of ER-positive, HER2-negative breast cancer is associated with relapse on tamoxifen.
Snell CE; Gough M; Middleton K; Hsieh M; Furnas L; Seidl B; Gibbons K; Pyke C; Shannon C; Woodward N; Armes JE
J Clin Pathol; 2017 Nov; 70(11):954-960. PubMed ID: 28416639
[TBL] [Abstract][Full Text] [Related]
40. Determining HER2 (ERBB2) amplification status in women with breast cancer: final results from the Australian in situ hybridisation program.
Morey AL; Brown B; Farshid G; Fox SB; Francis GD; McCue G; von Neumann-Cosel V; Bilous M
Pathology; 2016 Oct; 48(6):535-42. PubMed ID: 27567228
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
